Huang Tom Hsun-Wei, Razmovski-Naumovski Valentina, Kota Bhavani Prasad, Lin Diana Shu-Hsuan, Roufogalis Basil D
Faculty of Pharmacy, A15, University of Sydney, New South Wales, 2006, Australia.
Respir Res. 2005 Sep 9;6(1):102. doi: 10.1186/1465-9921-6-102.
Research into respiratory diseases has reached a critical stage and the introduction of novel therapies is essential in combating these debilitating conditions. With the discovery of the peroxisome proliferator-activated receptor and its involvement in inflammatory responses of cardiovascular disease and diabetes, attention has turned to lung diseases and whether knowledge of this receptor can be applied to therapy of the human airways. In this article, we explore the prospect of peroxisome proliferator-activated receptor-gamma as a marker and treatment focal point of lung diseases such as asthma, chronic obstructive pulmonary disorder, lung cancer and cystic fibrosis. It is anticipated that peroxisome proliferator-activated receptor-gamma ligands will provide not only useful mechanistic pathway information but also a possible new wave of therapies for sufferers of chronic respiratory diseases.
对呼吸系统疾病的研究已进入关键阶段，引入新疗法对于对抗这些使人衰弱的病症至关重要。随着过氧化物酶体增殖物激活受体的发现及其在心血管疾病和糖尿病炎症反应中的作用，人们的注意力已转向肺部疾病，以及该受体的相关知识是否可应用于人类气道的治疗。在本文中，我们探讨了过氧化物酶体增殖物激活受体γ作为哮喘、慢性阻塞性肺疾病、肺癌和囊性纤维化等肺部疾病的标志物和治疗焦点的前景。预计过氧化物酶体增殖物激活受体γ配体不仅将提供有用的机制途径信息，还将为慢性呼吸系统疾病患者带来一波可能的新疗法。
